Very high remission rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab: Year 2 clinical results of an investigator-initiated randomised, controlled clinical trial of early, rheumatoid arthritis

Kim Hørslev-Petersen; Merete Lund Hetland; P. Junker; Jan Pødenphanth; T. Ellingsen; P. Ahlqvist; H.M. Lindegaard; A. Linauskas; A. Schlemmer; M.Y. Dam; I. Hansen; T. Lottenburger; A. Jørgensen; Sophine Boysen Krintel; J. Raun; C.G. Ammitzbøll; Julia Sidenius Johansen; Mikkel Østergaard

Very high remission rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab: Year 2 clinical results of an investigator-initiated randomised, controlled clinical trial of early, rheumatoid arthritis

Kim Hørslev-Petersen, Merete Lund Hetland, P. Junker, Jan Pødenphanth, T. Ellingsen, P. Ahlqvist, H.M. Lindegaard, A. Linauskas, A. Schlemmer, M.Y. Dam, I. Hansen, T. Lottenburger, A. Jørgensen, Sophine Boysen Krintel, J. Raun, C.G. Ammitzbøll, Julia Sidenius Johansen, Mikkel Østergaard

Original language	English
Journal	Arthritis & Rheumatism
Volume	65
Issue number	Suppl. 10
Pages (from-to)	S1148
Number of pages	1
ISSN	0004-3591
Publication status	Published - 2013

Cite this

Hørslev-Petersen, K., Hetland, M. L., Junker, P., Pødenphanth, J., Ellingsen, T., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Jørgensen, A., Krintel, S. B., Raun, J., Ammitzbøll, C. G., Johansen, J. S., & Østergaard, M. (2013). Very high remission rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab: Year 2 clinical results of an investigator-initiated randomised, controlled clinical trial of early, rheumatoid arthritis. Arthritis & Rheumatism, 65(Suppl. 10), S1148.

Very high remission rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab: Year 2 clinical results of an investigator-initiated randomised, controlled clinical trial of early, rheumatoid arthritis. / Hørslev-Petersen, Kim; Hetland, Merete Lund; Junker, P. et al.
In: Arthritis & Rheumatism, Vol. 65, No. Suppl. 10, 2013, p. S1148.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Hørslev-Petersen, K, Hetland, ML, Junker, P, Pødenphanth, J, Ellingsen, T, Ahlqvist, P, Lindegaard, HM, Linauskas, A, Schlemmer, A, Dam, MY, Hansen, I, Lottenburger, T, Jørgensen, A, Krintel, SB, Raun, J, Ammitzbøll, CG, Johansen, JS & Østergaard, M 2013, 'Very high remission rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab: Year 2 clinical results of an investigator-initiated randomised, controlled clinical trial of early, rheumatoid arthritis', Arthritis & Rheumatism, vol. 65, no. Suppl. 10, pp. S1148.

Hørslev-Petersen K, Hetland ML, Junker P, Pødenphanth J, Ellingsen T, Ahlqvist P et al. Very high remission rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab: Year 2 clinical results of an investigator-initiated randomised, controlled clinical trial of early, rheumatoid arthritis. Arthritis & Rheumatism. 2013;65(Suppl. 10):S1148.

Hørslev-Petersen, Kim ; Hetland, Merete Lund ; Junker, P. et al. / Very high remission rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab: Year 2 clinical results of an investigator-initiated randomised, controlled clinical trial of early, rheumatoid arthritis. In: Arthritis & Rheumatism. 2013 ; Vol. 65, No. Suppl. 10. pp. S1148.

@article{83dc7138d09a4c789b01148d77f392e6,

title = "Very high remission rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab: Year 2 clinical results of an investigator-initiated randomised, controlled clinical trial of early, rheumatoid arthritis",

author = "Kim H{\o}rslev-Petersen and Hetland, {Merete Lund} and P. Junker and Jan P{\o}denphanth and T. Ellingsen and P. Ahlqvist and H.M. Lindegaard and A. Linauskas and A. Schlemmer and M.Y. Dam and I. Hansen and T. Lottenburger and A. J{\o}rgensen and Krintel, {Sophine Boysen} and J. Raun and C.G. Ammitzb{\o}ll and Johansen, {Julia Sidenius} and Mikkel {\O}stergaard",

year = "2013",

language = "English",

volume = "65",

pages = "S1148",

journal = "Arthritis & Rheumatism",

issn = "0004-3591",

publisher = "John/Wiley & Sons, Inc. John/Wiley & Sons Ltd",

number = "Suppl. 10",

}

TY - ABST

T1 - Very high remission rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab: Year 2 clinical results of an investigator-initiated randomised, controlled clinical trial of early, rheumatoid arthritis

AU - Hørslev-Petersen, Kim

AU - Hetland, Merete Lund

AU - Junker, P.

AU - Pødenphanth, Jan

AU - Ellingsen, T.

AU - Ahlqvist, P.

AU - Lindegaard, H.M.

AU - Linauskas, A.

AU - Schlemmer, A.

AU - Dam, M.Y.

AU - Hansen, I.

AU - Lottenburger, T.

AU - Jørgensen, A.

AU - Krintel, Sophine Boysen

AU - Raun, J.

AU - Ammitzbøll, C.G.

AU - Johansen, Julia Sidenius

AU - Østergaard, Mikkel

PY - 2013

Y1 - 2013

M3 - Conference abstract in journal

SN - 0004-3591

VL - 65

SP - S1148

JO - Arthritis & Rheumatism

JF - Arthritis & Rheumatism

IS - Suppl. 10

ER -